VendiBean Co-Founder Reveals Key to Finding Work/Life Balance

 

Teal Cooper, co-founder of San Diego-based VendiBean LLC, joins hosts David and Matthew Shields of the “Like It’s Your Job” podcast from TSG Publishing to pull back the curtain on how her high-end espresso vending business is “disrupting” the coffee vending machine industry.

“My senior year, we saw a huge gap in the market for high-quality coffee that was conveniently located on-the-go, 24/7, on college campuses,” she says, recalling the early days of the venture.

With VendiBean’s five-year birthday right around the corner, the strategic consultants with the Shields Group interview Cooper about lessons learned and best practices from the enterprise she started with her own sibling, Tristan Cooper.

“The idea really came while I was studying abroad and saw the concept of a high-end espresso machine overseas,” Teal Cooper imparts to the podcast hosts. “My brother called me with the same idea, coincidentally — and we knew we had to do it.”

So, in early 2017, Teal Cooper and her brother set out with the simple objective of filling the dearth of high-quality coffee locations available around-the-clock on college campuses. But, as neither of the budding entrepreneurs had any background in making coffee or operating a business, they came across many unexpected hurdles on their path to success.

“We had to get our hands dirty,” she admits.

Five years later, VendiBean boasts 200 machines in three states and a staff of 10 employees.

As with many of their interview subjects, David and Matthew Shields touched on the successes, failures and lessons learned by a young business entrepreneur launching their own company. But with this episode in particular, the brothers engaged Teal Cooper in a lengthier exploration about how she found a work/life balance as her enterprise soared.

Listen to the full episode of “Like It’s Your Job” to hear how the highly motivated young professionals are finding ways to lower stress levels in their professional and personal lives — and how they can even carve out a “happy place” in the day-to-day work grind (literally, in Teal Cooper’s case).

For more information on the “Like It’s Your Job” podcast, check out the podcast’s page on Apple Podcasts. To explore Teal Cooper’s own podcast, “Real with Teal,” go to its website.

Follow us on social media for the latest updates in B2B!

Image

Latest

vitro
Analyzing the Suppressive TME in In Vitro Based Assays
April 19, 2025

In the rapidly advancing field of cancer immunotherapy, accurately modeling the tumor microenvironment (TME) has become essential to improving the predictive power of preclinical drug testing. As immune-modulating therapies surge forward, with over 4,000 immune modulators in development globally, scientists are refining assay technologies that maintain the complexity of patient-specific tumor biology. In vitro platforms…

Read More
cancer
Targeting T Cells Within the Cancer Immunity Cycle
April 19, 2025

As cancer immunotherapy continues to reshape treatment landscapes, fine-tuning T-cell responses has become a critical frontier. Recent advances in 3D organoid models and high-content imaging are enabling scientists to closely mimic patient-specific tumor environments—unlocking insights into how T cells behave, respond, and falter under immune checkpoint blockade. With over 4,000 immune modulators in clinical…

Read More
cancer Immunity cycle
Advanced In Vitro Technologies to Investigate Therapeutic Impact on the Cancer Immunity Cycle
April 19, 2025

As immunotherapy revolutionizes cancer treatment, the need for physiologically relevant preclinical models becomes more urgent than ever. Despite the success of immune checkpoint inhibitors, a large majority of patients fail to achieve long-lasting responses, prompting researchers to explore more complex and predictive assays. The cancer immunity cycle, first described in 2013, remains a central framework…

Read More
resistance
Inside Oncology Drug Development: Overcoming Resistance with Science
April 19, 2025

In the last two decades, oncology has undergone a transformation with over 300 new cancer therapies approved by the FDA—many offering novel mechanisms of action. Despite these innovations, resistance to treatment remains a critical challenge, with cancer cells evolving or adapting to evade even the most advanced therapeutics. This issue is particularly pressing given that…

Read More